Your browser doesn't support javascript.
loading
Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.
Domachowske, Joseph B; Chang, Yue; Atanasova, Victoria; Cabañas, Fernando; Furuno, Kenji; Nguyen, Kim A; Banu, Irfana; Kubiak, Robert J; Leach, Amanda; Mankad, Vaishali S; Shroff, Manish; Takas, Therese; Villafana, Tonya; Wählby Hamrén, Ulrika.
Affiliation
  • Domachowske JB; Department of Pediatrics, SUNY Upstate Medical University, Syracuse, New York, USA.
  • Chang Y; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Atanasova V; UMHAT Dr. G. Stranski EAD, Clinic of Neonatology, Pleven, Bulgaria.
  • Cabañas F; Department of Paediatrics-Neonatology, Quironsalud Madrid University Hospital and Quironsalud San José Hospital, Madrid, Spain.
  • Furuno K; Department of General Pediatrics and Interdisciplinary Medicine, Fukuoka Children's Hospital, Fukuoka, Japan.
  • Nguyen KA; Hospices Civils de Lyon, Hôpital Femme-Mere-Enfant, Service de Réanimation Néonatale et de Neonatologie (NICU) et CIC 1407, Lyon, France.
  • Banu I; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Kubiak RJ; Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Leach A; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Mankad VS; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Durham, North Carolina, USA.
  • Shroff M; Patient Safety, Chief Medical Office, R&D, AstraZeneca, Waltham, Massachusetts, USA.
  • Takas T; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Villafana T; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Wählby Hamrén U; Clinical Pharmacology and Quantitative Pharmacology, R&D, AstraZeneca, Gothenburg, Sweden.
J Pediatric Infect Dis Soc ; 12(8): 477-480, 2023 Aug 31.
Article in En | MEDLINE | ID: mdl-37466917
In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporting efficacy in this population at risk of severe RSV disease.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Respiratory Syncytial Virus, Human / Respiratory Syncytial Virus Infections / Lung Diseases Limits: Child / Humans / Infant Language: En Journal: J Pediatric Infect Dis Soc Year: 2023 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Respiratory Syncytial Virus, Human / Respiratory Syncytial Virus Infections / Lung Diseases Limits: Child / Humans / Infant Language: En Journal: J Pediatric Infect Dis Soc Year: 2023 Type: Article Affiliation country: United States